ARCHIVES

Sanofi: Zaltrap Price Reflects Competing Drugs In Second-Line Metastatic Colon Cancer

This article is from The Cancer Letter archive.

Vol. 38 No. 41 | November 1, 2012

Download PDF Visit The Full Archive

Related Articles

Adherez Issued U.S. Patent for Catenin Molecule Inhibition.

July 4, 2003

In Brief; NCAB Goes Along With NCI Staff In Funding EORTC Statistical Center Grant Out Of Priority Sequence

November 20, 1981

NCI Would Add Money For Centers If Number Go Up, Greenwald Says; Five Options For Changes Listed

April 27, 1984

Tivozanib Trumps Sorafenib In 1st-Line Renal Cancer Study

May 25, 2012

NCI Initiative: Start With Mechanism, Then answer The Many Questions, Klauser Says to Advisors

November 29, 1996

Community Based Organizing Nearly Complete; Conn. Still Planning

November 25, 1977